Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01491932 · ClinicalTrials.gov registry record · Phase 2
Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
A Phase 2 study of Parkinson Disease and Movement Disorders, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
- 20
- Study locations
NCT01491932: Completed Phase 2 study of Parkinson Disease and Movement Disorders, sponsored by Novartis Pharmaceuticals.
NCT01491932 is a Phase 2 study of Parkinson Disease and Movement Disorders that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 129 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01491932, a Phase 2 study of Parkinson Disease and Movement Disorders, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is to evaluate long-term safety, tolerability and efficacy for AFQ056 in patients who have completed an AFQ056A study in Parkinson's disease L-dopa induced dyskinesias (PD-LID).
Primary Outcome
The occurrence of adverse events would be sought by non-directive questioning of the patient at each visit. Adverse events may also be detected when they are volunteered by the patient during or between visits or through physical examination, laboratory test, or other assessment.
Conditions Studied
Interventions
- DRUG AFQ056
Study Locations (20)
Other
- Novartis Investigative Site - Innsbruck
- Novartis Investigative Site - Linz
- Novartis Investigative Site - Vienna
- Novartis Investigative Site - Clermont-Ferrand
- Novartis Investigative Site - Lille
- Novartis Investigative Site - Pessac
- Novartis Investigative Site - Beelitz-Heilstätten
- Novartis Investigative Site - Berlin
- Novartis Investigative Site - Bochum
- Novartis Investigative Site - Kassel
- Novartis Investigative Site - Leipzig
- Novartis Investigative Site - München
- Novartis Investigative Site - Stadtroda
- Novartis Investigative Site - Westerstede/Oldenburg
- Novartis Investigative Site - Kaposvár
- Novartis Investigative Site - Szeged
Colorado
- Novartis Investigative Site - Englewood
Kansas
- Novartis Investigative Site - Kansas City
Wisconsin
- Novartis Investigative Site - Milwaukee
Ontario
- Novartis Investigative Site - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2012-03 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
What the finished NCT01491932 record still lists
NCT01491932 is an interventional study that assigns participants to a tested intervention. The registered 129 participants enrollment target is mid-sized for trials with a published cap, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower).
The record links to 5 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which AFQ056 is the first listed.
NCT01491932 names 20 study sites across 5 states, led by Other, Colorado, Kansas.
Frequently Asked Questions
What is clinical trial NCT01491932 about?
NCT01491932 is a clinical study titled "Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias". This study is to evaluate long-term safety, tolerability and efficacy for AFQ056 in patients who have completed an AFQ056A study in Parkinson's disease L-dopa induced dyskinesias (PD-LID).
What is the current status of trial NCT01491932?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2012-03. Estimated completion is 2013-10.
What conditions does trial NCT01491932 study?
This clinical trial studies the following conditions: Parkinson Disease, Movement Disorders, Dyskinesias, Parkinsonian Disorders, Anti-Dyskinesia Agents.
What interventions are being tested in trial NCT01491932?
The interventions under investigation include: AFQ056 (DRUG).
Who is sponsoring clinical trial NCT01491932?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01491932 being conducted?
This trial has 20 study locations across Colorado, Kansas, Wisconsin, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01491932's enrollment target sits among peer trials
129 64th of 297 higher than 234 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
-
Pyridostigmine for the Treatment of Constipation in Parkinson Disease
RECRUITING · Phase 2
-
Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease
RECRUITING · Phase 2
-
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
RECRUITING · Phase 2
-
Rehabilitation of Airway Protection in Parkinson's Disease
RECRUITING · Phase 2
-
Psilocybin Therapy for Depression in Parkinson's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03619850 · 129 participants · Phase 3
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
- NCT05704361 · 129 participants · Phase 1
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
- NCT05919849 · 129 participants · Phase 1
Supporting Parents in Affirming Their Children's Experiences of Stigma
- NCT06313749 · 129 participants · NA
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia